COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CLGNCollPlant(CLGN) Prnewswire·2024-08-20 19:00
  • Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company deve ...